Medline Inc. MDLN
Nov 5, 2026, 9:41 AM EST
- YTD
- -2.43%
- 1 year
- -0.05%
- Market cap
- 55.08B
- Revenue (ttm)
- 29.94B
- Profit margin
- 2.31%
- EPS (ttm)
- 0.44
- Shares out
- 877.35M
- P/E ratio
- 93.05
- Forward P/E
- 25.71
- YTD return
- -2.43%
- 1-year return
- -0.05%
- Volume
- 297.07K
- Avg volume
- 8.73M
- Open
- 40.35
- Previous close
- 40.35
- Day's range
- 40.34 – 41.60
- 52-week range
- 31.37 – 50.88
- Analysts
- Buy
- Price target
- 44.31 (+8.1%)
- Earnings date
- Feb 24, 2027
5D +7.80 (+23.96%)
Key statistics
- Enterprise value
- 47.35B
- PEG ratio
- 0.00
- Price / sales
- 1.81
- Price / book
- 3.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 11.60%
- Free cash flow
- 850.63M
- Total cash
- 2.70B
- Total debt
- 12.64B
- Return on equity
- 4.93%
- Short % of float
- 9.69%
- 50-day average
- 34.48
- 200-day average
- 39.55
Analyst view
Consensus: buy
- Target (low)
- 34.00
- Target (mean)
- 44.31
- Target (high)
- 55.00
- Strong buy7
- Buy16
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.3463.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 26, 2026 | 0.39 | — | — | — |
| Nov 4, 2026 | Sep 26, 2026 | 0.3432 | 0.44 | +0.10 | +28.21% |
| Aug 5, 2026 | Jun 27, 2026 | 0.3524 | 0.50 | +0.15 | +41.88% |
| May 6, 2026 | Mar 31, 2026 | 0.2952 | 0.33 | +0.03 | +11.79% |
| Feb 25, 2026 | Dec 31, 2025 | 0.2381 | 0.2247 | -0.01 | -5.63% |
| Nov 4, 2025 | Sep 30, 2025 | — | 0.31 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | Mizuho | main | Outperform | Outperform |
| Oct 9, 2026 | Barclays | main | Overweight | Overweight |
| Sep 25, 2026 | UBS | main | Buy | Buy |
| Aug 27, 2026 | BTIG | reit | Buy | Buy |
| Aug 12, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 11, 2026 | Tigress Financial | main | Buy | Buy |
About Medline Inc.
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- medline.com
News
Medline Q3 Earnings Call Highlights
Medline Q3 2026 Earnings Call Transcript
Medline (MDLN) Reports Q3 Earnings: What Key Metrics Have to Say
Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday Medline Announces $1B Buyback Plan
Medline Q3 Adj. EPS $0.44 Beats $0.35 Estimate, Sales $7.856B Beat $7.723B Estimate
Medline Reports Third Quarter and Nine Months 2026 Results
MDLN Investigation Reminder: Medline Product Quality Issues Trigger Securities Fraud Investigation for Investors – Contact BFA Law if You Lost Money
ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test
Medline announces participation in the 2026 Jefferies Global Healthcare Conference
Your note
Sign in to keep a note on MDLN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BX MOZART ML-1 HOLDCO L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 20, 2026 | 0 |
| BX MOZART ML-2 HOLDCO L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | May 27, 2026 | 0 |
| CARLYLE GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 9, 2026 | 0 |
| GIC PRIVATE LTD | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 7, 2026 | 0 |
| HELLMAN & FRIEDMAN CAPITAL PARTNERS X PARALLEL, L.P | Beneficial Owner of more than 10% of a Class of Security | Sale | May 27, 2026 | 0 |
| MILLS ANDREW J. | Director | Purchase | Dec 17, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Carlyle Group Inc. | 21.32% | 187,083,713 | 7.55B | Jun 29, 2026 |
| Blackstone Inc | 11.60% | 101,791,008 | 4.11B | Jun 29, 2026 |
| H&f Corporate Investors X, Ltd. | 8.08% | 70,874,326 | 2.86B | Jun 29, 2026 |
| FMR, LLC | 5.35% | 46,963,203 | 1.89B | Jun 29, 2026 |
| Capital Research Global Investors | 4.56% | 39,963,790 | 1.61B | Jun 29, 2026 |
| Invesco Ltd. | 4.37% | 38,346,937 | 1.55B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Amcap Fund | 2.14% | 18,780,959 | 757.81M | Sep 29, 2026 |
| Growth Fund of America | 1.58% | 13,853,297 | 558.98M | Sep 29, 2026 |
| Fidelity Contrafund | 1.53% | 13,411,899 | 541.17M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.41% | 12,406,857 | 500.62M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 0.96% | 8,466,394 | 341.62M | Jun 29, 2026 |
| MFS SERIES TRUST I-MFS Value Fund | 0.78% | 6,853,598 | 276.54M | Aug 30, 2026 |
